Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Covagen partners bispecific FynomAbs with Mitsubishi Tanabe Pharma

Executive Summary

Large-molecule cancer and inflammation therapeutics developer Covagen AG has granted Mitsubishi Chemical Holdings Corp.’s Mitsubishi Tanabe Pharma Corp. an exclusive worldwide license to develop, manufacture, and sell its bispecific FynomAbs against up to two target pairs chosen by Mitsubishi Tanabe and its US biological drug discovery division Tanabe Research Laboratories USA Inc. (TRL).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies